Table 1 The relationship between the changes in sIgA levels in different compartments and the treatment group and baseline severity of disease (RLMEM).
From: Bacterial lysates in modifying sIgA levels in the upper respiratory tract in COVID-19 patients
Effects | Pharyngeal secretion | Saliva | Nasal secretion | |||
|---|---|---|---|---|---|---|
Less severe disease | More severe disease | Less severe disease | More severe disease | Less severe disease | More severe disease | |
Day 14 | p = 0.47 | p = 0.01 | p = 0.04 | p = 0.81 | p = 0.21 | p = 0.77 |
Day 30 | p = 0.62 | p = 0.97 | p = 0.06 | p = 0.02 | p = 0.15 | p = 0.21 |
Treatment group | p = 0.34 | p = 0.89 | p = 0.29 | p = 0.99 | p = 0.11 | p = 0.75 |
Day 14 time point × group | p = 0.75 | p = 0.89 | p = 0.46 | p = 0.49 | p = 0.29 | p = 0.91 |
Day 30 time point × group | p = 0.04 | p = 0.05 | p = 0.03 | p = 0.50 | p = 0.50 | p = 0.13 |
Model quality | Rm = 0.18 Rc = 0.18 | Rm = 0.19 Rc = 0.32 | Rm = 0.24 Rc = 0.24 | Rm = 0.16 Rc = 0.16 | Rm = 0.06 Rc = 0.06 | Rm = 0.04 Rc = 0.12 |
